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Abstract 
 
Cancer is a major cause of death worldwide and novel anticancer agents for its better management are much 
needed. Benzopyrone-based compounds, such as chromones, possess several distinctive chemical and 
biological properties, of which the cytotoxicity against cancer cells seems to be prominent. In this study, two 
series of compounds based on chromen-4-one (3-10) and chromane-2,4-dione (11-18) scaffolds were 
synthesized in moderate/high yields and evaluated for cytotoxicity against HL-60, MOLT-4, and MCF-7 
cancer cells using MTT assay. In general, the compounds exhibited moderate cytotoxic effects against the 
cancer cell lines, among which, a superior potency could be observed against MOLT-4 cells. Chroman-2,4-
dione (11-18) derivatives had overall higher potencies compared to their chromen-4-one (3-10) counterparts. 
Compound 13 displayed the lowest IC50 values against HL-60 (IC50, 42.0 ± 2.7 µM) and MOLT-4 cell lines 
(IC50, 24.4 ± 2.6 µM), while derivative 11 showed the highest activity against MCF-7 cells (IC50, 68.4 ± 3.9 
µM). In conclusion, this study provides important information on the cytotoxic effects of chromone 
derivatives. Benzochroman-2,4-dione has been identified as a promising scaffold, which its potency can be 
modulated by tailored synthesis with the aim of finding novel and dissimilar anticancer compounds. 
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INTRODUCTION 
 
Benzopyrone-based compounds, such as 
chromone, coumarin, and flavonoids have come 
to the attention of many investigators in recent 
years, due to their distinctive chemical and 
biological properties (1-4). In this context, 
benzopyran and its derivatives constitute an 
important class of natural compounds representing 
a broad range of biological activities such as 
antibacterial and antiviral (5,6), anticancer (7,8), 
antioxidant (5,9), anti-inflammatory (10), 
monoamine oxidase B inhibition (11-13), 
interaction with A3 adenosine receptor (14,15), 
and anticoagulant effects (16). Moreover, they are 
important intermediates in the synthesis of several 
natural products and medicinal agents (1,3,17).  
Cancer continues to be among one of the 
most important causes of death worldwide (18). 
Chemotherapeutic agents that are available today 
invariably suffer from poor toxicity profile and 
adverse effects that cause dose reduction and 
therefore lack of efficacy (19). Therefore, 
discovery of novel anticancer agents is one of 
the top priorities of drug discovery programs. In 
this regard, benzopyran based compounds, like 
chromones, may be regarded as privileged 
scaffolds for rational design of anti-cancer 
agents (20). Cytotoxic activity has been reported 
for several chromone derivatives such as                  
3-formylchromones (21), 2,3-diarylchromanones 
(22), 3-hydroxychromones (23), 4H-chromen-
1,2,3,4-tetrahydropyrimidine-5-carboxylates (24), 
3-(3-oxobenzofuran-2(3H)-ylidene)methyl)-4H-
chromones (25) and also for organometallic 
complexes of chromone derivatives (26).  
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The anticancer effect of these compounds 
has been reported against leukemia (22,25,27) 
and breast cancer cells (20,28,29). 
Furthermore, chromones seem also to exert 
antiproliferative effects against lung and colon 
cancer cells (8). Several derivatives of 
chromones seem to induce apoptosis in 
different cancer cells (28,29). 
In view of the literature evidence on the 
potential anticancer effect of chromone 
derivatives and also in continuation of our 
work on the development of novel heterocyclic 
based cytotoxic agents (30-32), herein we 
report on the synthesis, characterization, and  
in vitro cell based cytotoxic activities of a 
series of chromen-4-one and chromane-2,4-
dione derivatives. 
 
MATERIALS AND METHODS 
 
Reagents, general procedures, and apparatus  
3- (4,5-Dimethylthiazol-2-yl)- 2, 5- diphenyl-
tetrazolium bromide (MTT), benzotriazol-1-
yloxytripyrrolidinophosphonium hexafluoro-
phosphate (PyBOP), N,N-diisopropylethyl-
amine (DIPEA), chromone-2-carboxylic (1), 
and chromone-3-carboxylic (2) acids as well 
as primary amines were obtained from Sigma-
Aldrich (USA).  
Fetal bovine serum (FBS), RPMI1640, 
phenol red free RPMI1640, phosphate 
buffered saline (PBS), trypsin, and trypan blue 
were purchased from Biosera (France). 
Penicillin/streptomycin was purchased from 
Invitrogen (USA). Dimethyl sulfoxide 
(DMSO) and cisplatin were from Merck 
(Germany) and EBEWE Pharma (Austria), 
respectively. All other reagents and solvents 
were pro analysis grade and acquired from 
Merck, Sigma-Aldrich (USA) and PanReac 
AppliChem (Germany) and used without 
further purification.  
Thin-layer chromatography (TLC) was 
carried out on pre-coated silica gel 60 F254 
(Merck, Portugal). The thickness of TLC layer 
was 0.2 mm. The spots were visualized under 
UV detection at 254 and 366 nm. Flash 
column chromatography was performed using 
silica gel 60 (0.2-0.5 or 0.040-0.063 mm; 
Carlo Erba, Portugal). The organic phases 
were dried over anhydrous Na2SO4 after 
workup and extraction. Whenever needed, the 
solutions were decolorized using activated 
charcoal. A Buchi Rotavapor® (Switzerland) 
was used to evaporate the solvents. 
Proton nuclear magnetic resonance                  
(1H NMR) and carbon-13 NMR (13C NMR) 
data were acquired, at room temperature, on a 
Brüker AMX 400 spectrometer (Spain) 
operating at 400.15 and 100.63 MHz, 
respectively. Chemical shifts were expressed 
in δ (ppm) values relative to tetramethylsilane 
(TMS) as internal reference; coupling 
constants (J) were reported in Hz. Electron 
impact mass spectra (EI-MS) were carried out 
on a VG AutoSpec instrument (Spain); the 
data were reported as m/z (% of relative 
intensity of the most important fragments).  
 
General synthesis procedure  
A solution of PyBOP (1 mmol) in 
dichloromethane (2.5 mL) was added to a 
solution of chromone carboxylic acid                  
(1 mmol) in dimethylformamide (2.5 mL) and 
DIPEA (1 mmol) at 4 °C. The mixture was 
stirred on ice for 30 min. Afterwards the 
(hetero) aromatic amine was added to the 
reaction that was then warmed up to the 
ambient temperature. Then, the reaction was 
stirred for 4 h. The crude product was 
extracted (CH2Cl2) and purified by flash 
chromatography (CH2Cl2/MeOH or EtOAc/n-
hexane). Final purification was performed by 
recrystallization (EtOAc/n-hexane).  
 
N- Cyclohexyl - 4- oxo - 4 H –chromene - 2 -
carboxamide (3)  
Yield: 60%. 1H NMR (CDCl3): δ = 1.73 – 
1.18 (6H, m, 2 x H(3’), 2 x H(4’), 2 x H(5’)), 
2.11 – 1.74 (4H, m, 2 x H(2’), 2 x H(6’)), 4.06-
3.91 (1H, m, H(1’)), 6.70 (1H, d, J = 7.2, 
CONH), 7.17 (1H, s, H(3)), 7.45 (1H, ddd,             
J = 8.1, 7.2, 1.0, H(6)), 7.53 (1H, dd, J = 8.5, 
0.6, H(8)), 7.74 (1H, ddd, J = 8.7, 7.2, 1.7, 
H(7)), 8.22 (1H, dd, J = 8.0, 1.5 Hz, H(5)). 13C 
NMR (DMSO): 24.9 (C3’, C5’), 25.4 (C4’), 
32.9 (C2’, C6’), 49.1 (C1’), 112.1 (C3), 118.0 
(C8), 124.4 (C4a), 125.9 (C6), 126.2 (C5), 
134.4 (C7), 155.0 (C8a), 155.3 (C2), 158.2 
(CONH), 178.2 (C4). EI-MS m/z: 271 (M+•, 
38), 228 (12), 191 (19), 190 (100), 173 (16), 
145 (12), 89 (39). 
Gaspar et al. / RPS 2019; 14(1): 74-83 
 
76 
 
N- Phenyl - 4 -oxo - 4H – chromene – 2 -
carboxamide (4)  
Yield: 81 %. 1H NMR (DMSO): δ = 6.99 
(1H, s, H(3)), 7.21 (1H, ddd, J = 7.6, 7.5, 1.1 
H(4’)) 7.44 (2H, ddd, J = 7.0, 6.9, 1.8, H(3’), 
H(5’)), 7.58 (1H, ddd, J = 8.0, 6.9, 1.1, H(6)), 
7.81 (2H, dd, J = 8.1, 1.1, H(2’), H(6’)), 7.86 
(1H, dd, J = 8.3, 0.8, H(8)), 7.95 (1H, ddd, J = 
8.5, 6.8,1.6, H(7)), 8.10 (1H, dd, J = 7.9, 1.6, 
H(5)), 10.77 (1H, s, CONH). 13C NMR 
(DMSO): δ = 111.1 (C3), 119.1 (C8), 121.1 
(C2’, C6’), 123.7 (C4a), 124.9 (C6), 125.0 
(C5), 126.2 (C4’), 128.9 (C3’, C5’), 135.1 
(C7), 137.5 (C1’), 155.2 (C8a), 155.7 (C2), 
157.8 (CONH), 177.4 (C4). EI-MS m/z: 265 
(M+•, 18), 264 (83), 236 (32), 145 (18), 117 
(19), 92 (1689 (100), 69 (15), 65 (16), 63 (19). 
 
N-(4-Chlorophenyl)-4-oxo-4H- chromene- 2 -
carboxamide (5)  
Yield: 50%. 1H NMR (DMSO): δ = 6.97 
(1H, s, H(3)), 7.48 (2H, d, J = 8.8, H(3’), 
H(5’)), 7.56 (1H, m, H(6)), 7.83-7.96 (4H, m, 
H(7), H(8), H(2’), H(6’)), 8.08 (1H, dd, J = 
7.9, 1.6, H(5)), 10.87 (1H, s, CONH). 13C 
NMR (DMSO): δ = 111.2 (C3), 119.0 (C8), 
122.7 (C2’, C6’), 123.7 (C4a), 125.0 (C5), 
126.2 (C6), 128.7 (C4’), 128.8 (C3’, C5’), 
135.2 (C7), 136.6 (C1’), 155.2 (C8a), 155.5 
(CONH), 157.9 (C2), 177.3 (C4). EI-MS m/z: 
301 (34), 300 (33), 299 (M+•, 100), 298 (50), 
282 (15), 270 (24), 173 (14), 145 (28), 101 
(18), 90 (10), 89 (89), 69 (16), 63 (14). 
 
N-(4- (Methylthio) phenyl)-4 -oxo- 4H -
chromene-2-carboxamide (6)  
Yield: 60%. 1H NMR (CDCl3): δ = 
2.51(3H, s, SCH3 ), 7.28 (1H, s, H(3)), 7.31 
(2H, d, J = 8.6, H(3’), H(5’)), 7.50 (1H, ddd, J 
= 8.0, 7.2, 1.0, H(6)), 7.60 (1H, d, J = 8.5, 
H(8)), 7.66 (2H, d, J = 8.6 H(2’), H(6’)), 7.78 
(1H, ddd, J = 8.0, 7.1, 1.0, H(7)), 8.26 (1H, dd, 
J = 8.0, 1.5, H(5)), 8.51 (1H, s, CONH)). 13C 
NMR (CDCl3): δ = 16.2 (SCH3), 112.7 (C3), 
118.0 (C8), 121.0 (C3’, C5’), 124.4 (C4a), 
126.2 (C5), 126.3 (C6), 127.6 (C2’, C6’), 
133.7 (C1’), 134.7 (C7), 135.74 (C4’), 154.4 
(C8a), 155.1 (C2), 156.8 (CONH), 178.7 (C4). 
EI-MS m/z: 312 (M+1, 21), 311 (M+•, 100), 
278 (16), 140 (11), 138 (65), 89 (23). 
 
N-(4- (Methylsulfonyl)phenyl ) -4 -oxo- 4H -
chromene -2- carboxamide (7)  
Yield: 54%. 1H NMR (DMSO): δ = 3.23 
(3H, s, CH3), 7.03 (1H, s, H(3)), 7.59 (1H, 
ddd, J = 8.1, 7.1, 1.1, H(6)), 7.86 (1H, dd, J = 
8.5, 0.7, H(8)), 7.98 – 7.92 (1H, m, H(7)), 
8.01-7.98 (2H, m, H(3’), H(5’)), 8.12-8.07 
(3H, m, H(2’), H(5), H(6’)), 11.10 (1H, s, 
NH). 13C NMR (DMSO): δ = 43.7 (CH3), 
111.5 (C3), 119.1 (C8), 121.0 (C2’, C6’), 
123.8 (C8a), 125.0 (C6), 126.3 (C5), 128.2 
(C3’, C5’), 135.2 (C7), 136.4 (C4’), 142.2 
(C1’), 155.1 (C8a), 155.2 (C2), 158.4 
(CONH), 177.3 (C4). EI-MS m/z: 343 (M+•, 
19), 343 (100), 214 (9).  
 
N- (2-Thiazolyl) -4-oxo- 4H-chromene- 2 -
carboxamide (8)  
Yield: 55%. 1H NMR (CDCl3): δ= 7.05 
(1H, s, H(3)), 7.38 (1H , d, J = 3.7, H(3’), 7.55 
(1H, ddd, J = 8.1, 7.0, 1.2, H(6)), 7.64 (1H, d, 
J = 3.7, H(4’)), 7.84 (1H, dd, J = 8.5, 0.8, 
H(8)), 7.90 (1H, ddd, J = 8.6, 7.0, 1.7, H(7)), 
8.06 (1H, dd, J = 8.0, 1.3 Hz, H(5)), 13.32 
(1H, bs, NH). 13C NMR (CDCl3): δ = 111.8 
(C3), 114.7 (C3’), 119.1 (C8), 124.9 (C4a, 
C6), 126.2 (C5), 135.1 (C7, C4’), 155.3 (C1’, 
C2, C8a, CONH), 159. 5 (C1’), 177.4 (C4). 
EI-MS m/z: 272.1 (M+•, 58), 244 (18), 216 
(13), 173 (49), 145 (30), 89 (100).  
 
N- (5-Methyl -2 -thiazolyl) – 4 - oxo- 4H -
chromene-2-carboxamide (9)  
Yield: 48%. 1H NMR (CDCl3): δ = 2.39 
(3H, d, J = 1.1 Hz, CH3), 7.04 (1H, s, H(3)), 
7.32 (1H, q, J = 1.1 Hz, H(4’)), 7.56 (1H, ddd, 
J = 8.1, 7.2, 1.1 Hz, H(6)), 7.83 (1H, d, J = 7.9 
Hz, H(8)), 7.91 (1H, ddd, J = 8.6, 7.1, 1.7 Hz, 
H(7)), 8.07 (1H, dd, J = 8.0, 1.4 Hz, H(5)).13C 
NMR (CDCl3): δ = 11.4 (CH3), 111.7 (C3), 
119.1 (C8), 123.8 (C3’), 124.9 (C4a, C6), 
126.1 (C5), 135.1 (C7, C4’), 155.4 (C1’, C2, 
C8a, CONH), 177.4 (C4). EI-MS m/z: 288 
(M+•, 53), 286 (86), 258 (72), 230 (62), 230 
(62), 173 (95), 145 (82) 68 (100). 
 
N- (Pyridin-2-yl )- 4-oxo - 4H-chromene – 2 -
carboxamide (10)  
Yield: 22%. 1H NMR (CDCl3): δ = 7.19 
(1H, ddd, J = 7.4, 5.0, 0.9, H(4’)), 7.30 (1H, s, 
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H(3)), 7.50 (1H, ddd, J = 8.1, 7.2, 1.0, H(6)), 
7.63 (1H, dd, J = 8.5, 0.6, H(6’)), 7.89-7.72 
(2H, m, H(5’),H(8)), 8.25 (1H, dd, J = 8.0,  
1.4, H(3’)), 8.45-8.32 (2H, m, H(5), H(7)), 
9.31 (1H, s, NH). 13C NMR (CDCl3):                        
δ = 113.0 (C3), 114.8 (C6’), 118.2 (C8), 121.1 
(C4’), 124.4 (C4a), 126.2 (C6), 126.3 (C5), 
134.9 (C7), 139.0 (C5’), 148.1 (C3’), 150.1 
(C1’), 154.0 (C8a), 155.2 (C2), 157.3 
(CONH), 177.9 (C4). EI-MS m/z: 267 (22), 
266 (M+•, 99), 238 (58), 237 (66), 210 (83),  
89 (100). 
 
(E/Z) - 3 - ((Cyclohexylamino) methylene) 
chromane-2,4-dione (11)  
Yield: 30%. 1HNMR (DMSO): δ = 1.32-
1.94 (10H, m, 2 x H(2’), 2 x H(3’), 2 x H(4’), 
2 x H(5’), 2 x H(6’)), 3.70 (1H, m, H(1’)), 
7.32 (2H, m, H(6), H(8)), 7.66 (1H, dd,               
J = 8.0, 7.3, H(7)), 8.02 (0.7H, d, J = 7.6, 
H(5)), 8.11 (0.3H, d, J = 7.6, H(5)), 8.44 
(0.7H, d, J = 14.8, H(CHNH)), 8.60 (0.3H, d,  
J = 14.8, H(CHNH)), 10.31 (0.3H, brs, NH), 
11.85 (0.7H, brs, NH). 13C NMR (DMSO): δ: 
23.89 (C), 24.41 (C), 30.74 (C,), 32.18 (C), 
35.75 (C), 58.56 (C1’), 95.6 (C3), 116.9 (C8), 
120.2 (C4a), 123.9 (C6), 125.2 (C5), 134.3 
(C7), 154.2 (C8a), 160.3 (CHNH), 162.4 (C2), 
179.6 (C4). EI-MS m/z: 271 (M+1, 100), 228 
(18), 188 (23), 175 (23), 173 (18), 121 (31), 97 
(22), 57 (17). 
 
(E/Z)-3- ((Phenylamino)methylene)chromane 
-2,4-dione (12)  
Yield 60%. 1H NMR (CDCl3) δ: 7.40-7.26 
(5H, m, H(2’), H(3’), H(4’), H(5’), H(6’)), 
7.52 - 7.45 (2H, m, H(6), H(8)), 7.64-7.57 
(1H, m, H(7)), 8.14 (0.7H, dd, J = 7.8, 1.6, 
H(5)), 8.08 (0.3H, dd, J = 7.8, 1.7, H(5)), 8.91 
(0.7H, d, J = 13.6, H(CHNH), 9.05 (0.3H, d,                           
J = 14.5, H(CHNH), 11,94 (0.3H, d, J = 13.8, 
NH), 13.70 (0.7H, d, J = 12.2, NH). 13C NMR 
(CDCl3) δ: 99.0/98.9 (C3), 117.6/117.5 (C8), 
118.6/118.7 (C2’, C6’), 120.9/120.5 (C4a), 
124.6/124.4 (C6), 126.7/126.0 (C5), 
127.7/127.5 (C4’), 130.4/130.3 (C3’, C5’), 
135.0/134.9 (C7), 137.9 (C1’), 154.9/153.6 
(C8a), 155.2/155.1 (CHNH), 165.4/163.8 
(C2), 182.0/178.8 (C4). EI-MS m/z: 266 (6), 
265(M+•, 61), 173 (100), 144 (16), 121 (35), 
117 (36). 
(E/Z)-3- ((4-Chlorophenyl)amino)methylene) 
chromane-2,4-dione (13)  
Yield: 47%. 1H NMR (DMSO) δ: 7.34 (1H, 
d, J = 7.8, H(8)), 7.38 (1H, dd, J = 7.6, 1.3, 
H(6)), 7.54 (2H, d, J = 8.8, (H3’), H(5’)),  
7.70-7.73 (3H, m, H(2’), H(6’), H(7)), 7.99 
(1H, dd, J = 7.8, 1.5 Hz , H(5)), 8.85 (0.7H, d, 
J = 13.8, CHNH), 8.88 (0.3H, d, J = 14.8, 
CHNH), 11.84 (0.3H, d, J = 14.8, NH), 11.84 
(0.3H, d, J = 14.8, NH), 13.39 (0.7H, d,               
J = 13.8, NH). 13C NMR (DMSO) δ: 98.3 
(C3), 117.2 (C8), 119.9 (C4a), 121.6/121.3 
(C2’, C6’), 124.3 (C5), 125.5 (C6), 
129.6/129.1 (C3’, C5’), 131.2 (C4’), 135.1 
(C7), 137.1 (C1’), 154.5 (C8a) 155.8/154.5 
(CHNH), 162.2 (C2), 180.3 (C4). EI-MS m/z: 
301 (37), 300 (21), 299 (M+•, 88), 174 (16), 
173(100), 151 (18), 121 (37), 92 (11), 89 (10). 
(E/Z) – 3 - ((4-(Methylthio)phenyl)amino) 
methylene)chromane-2,4-dione (14)  
Yield: 51%. 1H NMR (CDCl3) δ: 2.52 (3H, 
s, CH3), 7.35-7.25 (5H, m, H(6), H(8), H(2’), 
H(3’), H(5’), H(6’)), 7.64-7.57 (1H, m, H7), 
8.07 (0.7H, dd, J = 7.8, 1.7, H(5)), 8.14              
(1H, dd, J = 7.8, 1.7, H(5)), 8.85 (1H, d,                
J = 13.6 Hz, CHNH), 8.99 (0.3H, d, J = 14.5, 
CHNH), 11.93 (0.3H, d, J = 14.5, NH), 13.73 
(0.7 H, d, J = 13.2, NH). 13C NMR (DMSO) δ: 
15.9/15.8 (CH3), 98.8/98.7 (C3), 117.5/117.4 
(C8), 119.0/118.9 (C2’, C6’), 120.4                
(C4a), 124.5/124.2 (C5), 126.6/125.8 (C6), 
127.9/127.8 (C3’, C5’), 134.82/134.7 (C7), 
134.83 (C4’), 138.6/138.4 (C1’), 154.3/152.9 
(CHNH), 155.0 (C8a), 163.6 (C2), 181.8 (C4). 
EI-MS m/z: 313 (27), 312 (76), 311 (M+•, 
100), 296 (25), 174(29), 173(90), 148 (24), 
121 (70). 
 
(E/Z) - 3 - ((4-(Methylsulfonyl)phenyl)amino) 
methylene)chromane-2,4-dione (15)  
Yield: 47%. 1H NMR (DMSO) δ: 2.78 (3H, 
s, CH3), 7.40-7.33 (2H, m, H(8), H(6)),           
7.75-7.69 (1H, m, H(7)), 7.81-7.76 (2H, m, 
H(3’), H(5’)), 7.91-7.86 (2H, m, H(2’), H(6’)),            
8.00 (1H, dd, J = 7.8, 1.5, H(5)), 8.94 (0.7H, d, 
J = 13.7, CHNH), 8.97 (0.3H, d, J = 14.7, 
CHNH), 11.91 (0.3H, d, J = 14.7 Hz, NH), 
13.46 (0.7, d, J = 13.8, NH). 13C NMR 
(DMSO) δ: 43.1 (CH3), 98.6 (C3), 117.3/117.2 
(C8), 119.9 (C4a), 120.4/120.1 (C2’, C6’), 
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124.5/124.4 (C5), 125.3/125.2 (C3’, C5’), 
125.5 (C6), 135.2/135.1 (C7), 140.0 (C4’), 
144.5/1144.4 (C1’), 154.4/154.2 (C8a), 155.8 
(C2), 163.2/162.2 (CHNH), 180.5/177.5 (C4). 
EI-MS m/z: 343 (M+•, 17), 183(20), 173(21), 
155 (100). 
 
(E/Z)- 3 - ((Thiazol-2-ylamino) methylene) 
chromane-2,4-dione (16)  
Yield 15%. 1H NMR (CDCl3) δ: 7.17-7.13 
(1H, m, H(4’)) 7.36 – 7.25 (2H, m, H(8), 
H(7)), 7.59-7.55 (1H, m, H(3’)), 7.67-7.60 
(1H, m, H(6)), 8.07 (0.7H, dd, J = 7.8, 1.5, 
H(5)), 8.14 (0.3H, dd, J = 7.8, 1.5, H(5)), 9.18 
(0.7H, d, J = 11.9, CHNH), 9.25 (0.3H d,              
J = 13.1 Hz, CHNH), 12.20 (0.3H, d,                       
J = 12.4 Hz, NH), 13.97 (0.7H, d, J = 9.2 Hz, 
NH). 13C NMR (CDCl3) δ: 100.7/100.6 (C3), 
115.9/116.1 (C3’), 117.8/117.1 (C8), 
120.6/120.1 (C4a), 124.9/124.6 (C5), 
127.0/126.4 (C6), 135.8/135.5 (C7), 
141.3/141.1 (C4’), 153.2 (C8a), 154.8/153.3 
(CHNH), 159.8/159.7 (C2), 165.1/162.7 (C1’), 
182.8/178.7 (C4). EI-MS m/z: 272 (M+•, 58), 
173 (49), 145 (30), 89 (100). 
 
(E/Z) – 3 - ((5- Methylthiazol - 2 - yl)amino 
)methylene)chromane-2,4-dione (17)  
Yield 10%. 1H NMR (CDCl3) δ: 2.46 (5H, 
d, J = 1.3 Hz, CH3), 7.34-7.19 (3H m, H(3’), 
H(8), H(7)), 7.64-7.55 (1H, m, H(6)), 8.02 
(0.7H, dd, J = 7.8, 1.6, H(5)), 8.10 (0.3H, dd, J 
= 7.8, 1.6, H(5)), 9.04 (0.7H,), 9.12 (0.3H, s, 
CHNH), 12.08 (0.3H, brs, NH), 13.82 (0.7H, 
brs, NH). 13C NMR (CDCl3) δ: 12.2 (CH3), 
100.2/100.1 (C3), 117.6/117.5 (C8), 
120.5/120.0 (C4a), 124.7/124.4 (C5), 
126.8/126.2 (C6), 131.5/131.5 (C7), 
135.5/135.2 (C3’), 138.3/138.2 (C4’), 
154.3/152.7 (CHNH), 155.1/154.7 (C8a), 
157.5/157.3 (C2), 164.9/162.7 (C1’), 
182.4/178.5 (C4). EI-MS m/z: 286 (M+•, 100), 
258 (27), 188 (39), 173 (50), 121 (56), 90 (74). 
 
(E/Z)-3-((Pyridin-2-
ylamino)methylene)chromane-2,4-dione (18)  
Yield 61%. 1H NMR (DMSO) δ: 7.42 – 
7.28 (3H, m, H(4’), H(5’), H(6’)), 7.77-7.64 
(2H, m, H(6), H(8)), 8.05-7.90 (2H, m, H(3’), 
H(7’)), 8.50 (1H, d, J = 4.7, CHNH), 9.39 
(0.7H, d, J = 13.2, CHNH), 9.58 (0.3H, d,       
J = 14.1, CHNH), 11.84 (0.3H, d, J = 14.6 Hz, 
NH), 13.15 (0.7H, d, J = 13.1 Hz, NH), 13C 
NMR (DMSO) δ: 99.0/98.9 (C3), 114.9/114.6 
(C6’), 117.3/117.2 (C8), 120.0/120.2 (C4a), 
122.4/122.2 (C4’), 124.5/124.4 (C6), 
126.1/125.6 (C5), 135.4/135.3 (C7), 
139.6/139.5 (C5’), 148.8/148.7 (C3’), 
149.5/149.5 (C1’), 153.0/151.7 (C8a), 
154.5/154.3 (CHNH), 162.9/162.6 (C2), 
180.5/178 (C4). EI-MS m/z: 266 (M+•, 19), 
265 (55), 210 (30), 209 (100), 79 (35). 
 
Biological activity 
Cell lines and culture  
HL-60 (human promyelocytic leukemia), 
MOLT-4 cells (human acute lymphoblastic 
leukemia), and MCF-7 (human breast 
adenocarcinoma) were provided by Pasteur 
Institute of Iran (Tehran, I.R. Iran). The 
growth medium was prepared adding 10% 
FBS and antibiotics (penicillin-G and 
streptomycin) to RPMI1640 medium.  
 
MTT assay 
In order to evaluate the cytotoxic effect of 
synthesized compounds, MTT reduction assay 
was performed as described previously 
(33,34). Stock solutions of synthesized 
derivatives were prepared by their dissolving 
in DMSO. The stock solutions were diluted 
several times in growth medium in order to 
keep the final DMSO concentration below 
0.25%. Three cell lines including HL-60, 
MCF-7, and MOLT-4 at densities of 4 × 104, 3 
× 104 and 5×104 cells/mL, respectively, were 
plated in 96-well microplates (100 µL per 
well). The cells were cultured at 37 °C in 
humidified air (containing 5% CO2). Six wells 
were used as controls, which did not contain 
any synthetic compound. Blank wells were 
also used which contained only growth 
medium for background correction. After 24 h 
of incubation at 37 °C, 50 µL of the growth 
medium was removed and 50 µL media 
containing 3-4 different concentrations of 
synthesized derivative in the range 10-100 
µM, depending on the potency of the 
compound, were added in duplicate. In 
experiments with HL-60 and MOLT-4 cells 
the plates were centrifuged before media 
removal. After 72 h, the medium was removed 
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and replaced with 80 µL of MTT solution 
dissolved in RPMI without phenol red at a 
final concentration of 0.5 mg/mL and the 
plates were incubated for additional 4 h at              
37 °C. In order to solubilize the formazan 
crystals, 200 µL DMSO was added to each 
well. The optical density was measured at              
570 nm by a microplate reader. For each 
concentration of the test compounds, the 
percent viability was calculated compared to 
untreated cells and IC50 values were calculated 
with Curve Expert version 1.34 for Windows. 
Each test was repeated between 3-5 times.  
 
RESULTS 
 
Chemistry  
Two series of compounds based on 
chromen-4-one and chromane-2,4-dione 
scaffolds were synthesized by a 
straightforward one-pot synthetic strategy in 
moderate/high yields (Scheme 1). The 
chromone carboxamide derivatives from series 
I (3-10, Table 1) were obtained by the 
condensation of chromone-2-carboxylic acid 
(1) with the appropriate amine (Scheme 1) 
using the coupling reagent PyBOP in the 
presence of DIPEA (35-37). Chromane-2,4-
dione derivatives from series II (11-18,                
Table 1) were obtained with similar reaction 
conditions by using chromone-3-carboxylic 
acid (2) as starting material (Scheme 1). As it 
was previously reported (13), the high 
reactivity at C-2 position of the ester 
intermediate formed in situ between the 
carboxylic acid and PyBOP, changed the 
course of the reaction resulting in a 
nucleophilic attack by the (hetero) aromatic 
amine at C-2 position of the benzopyran ring. 
As stated before (13) after the ring-opening 
and the ring closing assisted-processes the 
formation of the chromane-2,4-dione 
derivatives took place in the reaction. 
 
Cytotoxic activity 
Chromone-3-carboxamide (3-10) and 
chromane-2,4-dione (11-18) derivatives were 
assayed for their cytotoxic activity on HL-60, 
MOLT-4, and MCF-7 cancer cells and IC50 
values are reported in Table 2 as mean ± SEM. 
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Scheme 1. Strategy followed to synthetize chromen-4-one and chromane-2,4-dione derivatives. a, Reagents:  PyBOP, 
benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate; DIPEA, N,N-diisopropylethylamine; RNH2. 
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Table 1. Structure and reaction yields of synthesized chromone-2-carboxamide (series I) and chromane-2,4-dione 
(series II) derivatives. 
 
 
Series I Series II 
R Compounds Yield (%) Compounds Yield (%) 
Cyclohexyl 3  60 11 30 
Phenyl 4 81 12 60 
4-Chlorophenyl 5 50 13 47 
4-(Methylthio)phenyl) 6 60 14 51 
4-(Methylsulfonyl)phenyl 7 54 15 47 
2-Thiazolyl 8 55 16 15 
5-Methyl-2-thiazolyl 9 48 17 10 
Pyridin-2-yl  10 22 18 61 
 
 
Table 2. Cell growth inhibitory activities of chromone-2-carboxamide (series I) and chromane-2,4-dione (series II) 
derivatives were assessed by the MTT reduction assay (IC50 values, µM; mean ± SEM). 
 
  
R 
Series I  Series II 
Compound HL-60 MCF-7 MOLT-4    Compound HL-60 MCF-7 MOLT-4 
Cyclohexyl 3 > 100 > 100 90.8 ± 1.2        11 64.6 ± 7.1 68.4 ± 3.9 33.2 ± 2.1 
Phenyl 4 > 100 > 100 > 100 12 > 50 > 50 47.1 ± 3.6 
4-Chlorophenyl 5 > 50 > 50 > 50 13 42.0 ± 2.7 > 50 24.4 ± 2.6 
4-(Methylthio)phenyl) 6 > 100 > 100 > 100 14 > 50 > 50 41.6 ± 4.1 
4(Methylsulfonyl)phenyl 7 > 50 > 50 > 50 15 71.8 ± 6.1 86.1 ± 19.0 48.6 ± 8.2 
2-Thiazolyl 8 > 100 > 100 > 100 16 95.2 ± 7.0 85.8 ± 9.7 48.5 ± 8.3 
5-Methyl-2-thiazolyl 9 > 100 > 100 > 100 17 91.5 ± 3.7 > 100 55.6 ± 3.6 
Pyridin-2-yl 10 > 100 > 100 > 100 18 > 50 > 50 > 50 
Cisplatin  2.7 ± 0.2 9.3 ± 2.4 2.9 ± 0.1     
 
DISCUSSION 
 
In this study, two series of compounds with 
chromen-4-one and chromane-2,4-dione 
scaffolds were synthesized and their 
cytotoxicity was assessed against 3 human 
cancer cell lines using MTT assay. Chroman-
2,4-dione (11-18) derivatives possessed higher 
cytotoxic capacities compared to their 
chromen-4-one (3-10) counterparts.  
Several benzopyran derivatives have been 
reported to hold considerable cytotoxic effects 
against cancer cells. A series of synthesized 
chromone derivatives based on lavendustin 
structure showed anticancer effects against A-
549 (lung adenocarcinoma) and HCT-15 
(colon adenocarcinoma) cells (8). Also 2,3-
diarylchromanones have shown potential 
cytotoxic effect against HL-60 promyelocytic 
leukemia cells (22). In another report, a series 
of 3-benzylidene-4-chromanones were 
synthesized and tested against MDA-MB-231 
(triple negative breast adenocarcinoma),             
SK-N-MC (neuroblastoma), and KB 
(nasopharyngeal carcinoma) cells. Some of the 
synthesized derivatives were more effective 
than etoposide, a standard chemotherapeutic 
agent, against these cancer cells (20).  
Different mechanisms of action have been 
proposed for the anticancer effect of                  
chromone derivatives. They have                  
been suggested to exert their effect via 
inhibition of topoisomerase enzymes (7,8,20). 
An in silico study has shown that                  
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4H-chromone-1,2,3,4-tetrahydropyrimidine -5-
carboxylates derivatives could be inhibitors of 
Bcr-Abl tyrosine kinase, which has important 
oncogenic functions in certain types of 
leukemia (27). Another investigation on breast 
and lung cancer cells has demonstrated that 
sulfonamide containing chromone derivatives 
possess inhibitory activity against carbonic 
anhydrase IX and XII, two important targets in 
certain types of cancer (29). 
Our findings showed that chroman-2,4-
dione derivatives possessed cytotoxic activity 
specially against leukemia cell lines and to a 
less extent against breast cancer cells. 
Although, the synthesized set of compounds in 
this study is not a numerous, in comparison 
with their anticancer activities (Table 2), the 
following structure activity relationships could 
be proposed: a) Chromane-2,4-dione 
derivatives (11-18) displayed a superior 
cytotoxicity profile when compared to the 
chromene-2-carboxamide compounds (3-10); 
b) Chromane derivatives (11-18) exhibited 
higher cytotoxic effects against MOLT-4 cell 
line compared to HL-60 or MCF-7 cell lines; 
3) The observed order of cytotoxic activity in 
MOLT-4 cell line was as follows: 13 > 11 > 
14 > 12 > 16 > 15 > 17 > 18; 4) In our 
synthesized series of compounds, it seems that 
the chromane-2,4-dione derivative bearing 
halogen in the exocyclic phenyl ring (13) 
shows the highest potency against MOLT-4 
and HL-60 cell lines; 5) Aromatization of the 
N-substituted ring reduced the cytotoxic 
activity against MOLT-4 cell line (12, IC50 = 
47.1 ± 3.6 and 11, IC50 = 33.2 ± 2.1 µM). 
 
CONCLUSION 
 
Our in vitro cell based cytotoxic evaluation 
showed that chromane-2,4-dione derivatives 
were better cytotoxic agents compared to 
chromone-2-carboxamide compounds against 
HL-60, MCF-7, and MOLT-4 human              
cancer lines. In particular, superior potencies 
have been detected in the case of                      
acute lymphoblastic leukemia (MOLT-4)                   
cells. Chromone-2-carboxamide compounds 
exhibited no cytotoxic activity against tested 
cancer cells; this activity loss may be related to 
the orientation of 2-carboxamide substituents 
in the site of action. The outcomes of this 
study may provide some information for 
rational discovery of chromane-2,4-dione 
based derivatives with the aim of finding more 
potent cytotoxic agents. 
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